Brief: T2 Biosystems Announce Participation In NIH-Funded Antibacterial Resistance Leadership Group Pilot Study For Pneumonia Patients
18/01/2024 14:06
Jan 18 (Reuters) - T2 Biosystems Inc TTOO.O :
* T2 BIOSYSTEMS ANNOUNCES PARTICIPATION IN NIH-FUNDED
ANTIBACTERIAL RESISTANCE LEADERSHIP GROUP (ARLG) PILOT STUDY FOR
PNEUMONIA PATIENTS
Source text for Eikon: ID:nGNX1yyy9W
Further company coverage: TTOO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on T2 Biosystems
See all newsBrief: T2 Biosystems Announces Intent To Wind Down Operations
Brief: T2 Biosystems Enters Amendment No. 12 To Term Loan Agreement
Brief: T2 Biosystems Announces Exclusive US Agreement With Cardinal Health To Sell Its FDA-Cleared Direct-From-Blood Diagnostics For Rapid Detection Of Sepsis-Causing Pathogens
T2 Biosystems Inc reports results for the quarter ended in June - Earnings Summary
Brief: T2 Biosystems Announces Commercial Expansion Through Malaysia And Indonesia Distributor